RGNX REGENXBIO Inc.

Investing.com -- Regenxbio Inc (NASDAQ:RGNX) shares rose 4.8% in premarket trading Friday after the company presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy at the Retina Society Annual Scientific Meeting.

With the Food and Drug Administration’s hard-liners gone, investors are rushing back into rare-disease bets.

Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome. The FDA placed the experimental gene therapy on clinical hold after spinal scans identified abnormalities in five treated participants, and Reuters reported that Regenxbio shares fell more than 24% in premarket trading following the announcement. The findings add […]

Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.

The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre

BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock.

Healthcare stocks were decreasing Monday afternoon, with the NYSE Healthcare Index and the State Str

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome.

Regenxbio said the FDA has placed a clinical hold on its Hunter syndrome therapy after the discovery of unusual spine MRI findings in five participants in a study.

REGENXBIO Inc. (NASDAQ:RGNX) shares tumbled 35% after the U.

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic

Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.

Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

REGENXBIO plans to sell $100 million worth of its common stock in an underwritten public offering.